Targeted ablation to block scar channels that cause ventricular tachycardia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study maps channels within scar tissue that conduct impulses causing ventricular tachycardia and then delivers targeted ablation near the identified exits. It uses noninvasive mapping to guide invasive high-density substrate and activation mapping during VT ablation, followed by ablation to block the exits. After ablation, the protocol includes attempting to induce VT again to evaluate immediate success and one-year outcomes. The approach relies on pacing within the scar to identify exit sites and uses proximal ablation around mapped exits to prevent reentry. Noninvasive mapping aims to streamline the invasive procedure and focus energy delivery within a small substrate area.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with structural heart disease undergoing VT ablation

Exclusion Criteria:

1. Unable or unwilling to sign consent
2. Cardiogenic shock or NYHA Class IV heart failure and not a candidate for mechanical circulatory support for the procedure (percutaneous left ventricular assist device (LVAD), extracorporeal membrane oxygenation, or implanted LVAD)
3. Absence of substrate during initial voltage mapping

Where it's running

• Westchester Medical Center
  Valhalla, New York, United States Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registry for patients receiving implantable cardioverter defibrillators

  This study is collecting information from hospitals about patients who receive implantable defibrillators to see how well these devices are helping people and to improve care for future patients.

  Recruiting American College of Cardiology · Washington D.C., District of Columbia · NCT01999140

• Identifying heart structure predictors of sudden cardiac death

  This study is trying to see if certain heart structure problems can help predict the risk of sudden cardiac death in patients with weak heart function who may need a defibrillator.

  Recruiting Johns Hopkins University · Newark, Delaware and 1 other locations · NCT01076660

• FAPI PET Imaging to See Fibroblast Activity in Nonischemic Cardiomyopathy

  This study tests whether a special PET/CT scan using 18F-AlF-NOTA-FAPI-04 can reveal active fibroblast activity in the hearts of adults with nonischemic cardiomyopathy to help understand disease behavior and guide care.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing · NCT07878338

• HB1011: a first-in-human test of heart-derived stem cells injected during bypass surgery

  This study tests whether a heart-derived stem cell therapy called HB1011 is safe to use during CABG surgery for people with ischemic cardiomyopathy.

  Recruiting Phase 1 HieraBio Inc. · Seongnam-si, Gyeonggi-do · NCT07861035

• Risk of malignant arrhythmias after acute coronary syndrome

  This study tracks how often dangerous heart rhythms occur in adults admitted for ACS and looks for patterns that might predict them.

  Recruiting Catharina Ziekenhuis Eindhoven · Eindhoven, North Brabant · NCT07824050

• Predict Arrhythmia Risk with Intelligent Software

  Researchers are testing AI-powered predictions to see if clinicians can spot patients at risk for dangerous heart rhythms using bedside ECG data.

  Recruiting Catharina Ziekenhuis Eindhoven · Eindhoven, North Brabant · NCT07792694

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.